PE20130312A1 - Una combinacion antitumoral que comprende ombrabulina, un derivado de taxano y un derivado de platino - Google Patents

Una combinacion antitumoral que comprende ombrabulina, un derivado de taxano y un derivado de platino

Info

Publication number
PE20130312A1
PE20130312A1 PE2012002429A PE2012002429A PE20130312A1 PE 20130312 A1 PE20130312 A1 PE 20130312A1 PE 2012002429 A PE2012002429 A PE 2012002429A PE 2012002429 A PE2012002429 A PE 2012002429A PE 20130312 A1 PE20130312 A1 PE 20130312A1
Authority
PE
Peru
Prior art keywords
derivative
administered
dose
ombrabulin
taxan
Prior art date
Application number
PE2012002429A
Other languages
English (en)
Inventor
Patrick Cohen
Ileana Corina Oprea
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP10305653A external-priority patent/EP2397135A1/en
Priority claimed from EP10306256A external-priority patent/EP2481404A1/en
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PE20130312A1 publication Critical patent/PE20130312A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) OMBRABULINA QUE SE ADMINISTRA A UNA DOSIS DE 15 A 35MG/M2; B) UN DERIVADO DE TAXANO TAL COMO PACLITAXEL QUE SE ADMINISTRA A UNA DOSIS DE 175 O 200MG/M2 O DOCETAXEL QUE SE ADMINISTRA A UNA DOSIS DE 60 O 75MG/M2; C) UN DERIVADO DE PLATINO TAL COMO CISPLATINO QUE SE ADMINISTRA A UNA DOSIS DE 75MG/M2 O CARBOPLATINO QUE SE ADMINISTRA A UNA DOSIS DE 5 O 6 AUC. DICHA COMBINACION ANTITUMORAL SE TOLERA BIEN, NO EXACERBA LA TOXICIDAD DE CADA UNO DE LOS AGENTES ANTITUMORALES Y ES UTIL EN EL TRATAMIENTO DE TUMORES SOLIDOS AVANZADOS ESTABILIZANDO O INDUCIENDO UNA REGRESION PARCIAL O COMPLETA DEL TUMOR
PE2012002429A 2010-06-18 2011-06-16 Una combinacion antitumoral que comprende ombrabulina, un derivado de taxano y un derivado de platino PE20130312A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10305653A EP2397135A1 (en) 2010-06-18 2010-06-18 An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
EP10306256A EP2481404A1 (en) 2010-11-15 2010-11-15 An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative

Publications (1)

Publication Number Publication Date
PE20130312A1 true PE20130312A1 (es) 2013-03-26

Family

ID=45347705

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012002429A PE20130312A1 (es) 2010-06-18 2011-06-16 Una combinacion antitumoral que comprende ombrabulina, un derivado de taxano y un derivado de platino

Country Status (22)

Country Link
US (1) US20130122113A1 (es)
EP (1) EP2582369A1 (es)
JP (1) JP2013528644A (es)
KR (1) KR20130088753A (es)
CN (1) CN103140224A (es)
AR (1) AR082005A1 (es)
AU (1) AU2011266635A1 (es)
BR (1) BR112012031917A2 (es)
CA (1) CA2802974A1 (es)
CO (1) CO6650420A2 (es)
DO (1) DOP2012000305A (es)
EA (1) EA201291268A1 (es)
EC (1) ECSP12012343A (es)
MA (1) MA34380B1 (es)
MX (1) MX2012014732A (es)
NI (1) NI201200183A (es)
PE (1) PE20130312A1 (es)
SG (1) SG186376A1 (es)
TN (1) TN2012000552A1 (es)
TW (1) TW201206419A (es)
UY (1) UY33457A (es)
WO (1) WO2011158206A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
PT1068870E (pt) 1998-04-03 2006-10-31 Ajinomoto Kk Agentes antitumorais
US20020183266A1 (en) 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
FR2838437B1 (fr) 2002-04-11 2004-06-04 Aventis Pharma Sa Procedes de preparation de combretastatines
FR2945210B1 (fr) * 2009-05-07 2011-07-01 Sanofi Aventis Combinaison antitumorale comprenant l'ave8062 et le sorafenib

Also Published As

Publication number Publication date
ECSP12012343A (es) 2012-12-28
CA2802974A1 (en) 2011-12-22
CN103140224A (zh) 2013-06-05
AR082005A1 (es) 2012-11-07
DOP2012000305A (es) 2013-01-31
MX2012014732A (es) 2013-01-22
TW201206419A (en) 2012-02-16
EP2582369A1 (en) 2013-04-24
CO6650420A2 (es) 2013-04-15
EA201291268A1 (ru) 2013-04-30
SG186376A1 (en) 2013-01-30
MA34380B1 (fr) 2013-07-03
US20130122113A1 (en) 2013-05-16
KR20130088753A (ko) 2013-08-08
BR112012031917A2 (pt) 2017-11-28
WO2011158206A1 (en) 2011-12-22
AU2011266635A1 (en) 2013-01-10
JP2013528644A (ja) 2013-07-11
NI201200183A (es) 2013-05-13
UY33457A (es) 2012-01-31
TN2012000552A1 (en) 2014-04-01

Similar Documents

Publication Publication Date Title
CY1122966T1 (el) 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CY1119714T1 (el) Ενωσεις αναστολεων
CO2020003478A2 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
NI201300074A (es) Novedosos derivados de azabencimidazol cíclico útiles como agentes antidiabéticos.
CY1118216T1 (el) Μεθοδοι αγωγης καρκινου
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
BR112015016681A8 (pt) uso de nanopartículas compreendendo paclitaxel e uma albumina, kit, medicamento, composição e forma de dosagem unitária para tratamento de câncer pancreático
GT201500312A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b
EA201792169A1 (ru) 5'-замещенные нуклеозидные соединения
MX2015011752A (es) Metodos para tratar cancer de pulmon.
DK1951729T3 (da) Oxygenbundne pyrimidinderivater
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
CY1123058T1 (el) Νευροπροστατευτικες δικυκλικες ενωσεις και μεθοδοι για τη χρηση τους στη θεραπεια διαταραχων του φασματος του αυτισμου και νευροαναπτυξιακων διαταραχων
PE20121520A1 (es) Formulacion farmaceutica que comprende ranolazina y dronedarona en el tratamiento de fibrilacion auricular
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
MX2015010829A (es) Compuestos terapeuticos y sus usos.
CY1122968T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει μια ενωση διαμινο-ετεροκυκλικου καρβοξαμιδιου ως δραστικο συστατικο
CL2016000026A1 (es) Nuevos derivados de azabencimidazol
CR20130569A (es) Análogos del ácido epoxieicosatrienoicos y métodos de toma y uso del mismo
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
CY1122357T1 (el) Αντικαρκινικος συνδυασμος που περιλαμβανει καμπαζιταξελη και σισπλατινη
PH12017502046A1 (en) Salts and prodrugs of 1-methyl-d-tryptophan
TR201819805T4 (tr) Flavaglin türevleri̇.
BR112018008076A2 (pt) derivados de lapachona contendo dois centros redox e métodos de uso dos mesmos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal